Amyloidosis Pipeline Review, H2 2015

1
Amyloidosis Pipeline Review, H2 2015
Published on October - 2015
2
.
Report Overview
About Amyloidosis Pipeline Review, H2
2015 Research Beam added report on Amyloidosis
Pipeline Review, H2 2015. Amyloidosis Pipeline
Review, H2 2015 Summary Global Markets Directs,
Amyloidosis Pipeline Review, H2 2015, provides an
overview of the Amyloidosis s therapeutic
pipeline. This report provides comprehensive
information on the therapeutic development for
Amyloidosis, complete with comparative analysis
at various stages, therapeutics assessment by
drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type, along
with latest updates, and featured news and press
releases. It also reviews key players involved in
the therapeutic development for Amyloidosis and
special features on late-stage and discontinued
projects. Get Full Details On
http//www.researchbeam.com/amyloidosis-pipeline-r
eview-h2-2015-market
3
.
Report Overview
Global Markets Directs report features
investigational drugs from across globe covering
over 20 therapy areas and nearly 3,000
indications. The report is built using data and
information sourced from Global Markets Directs
proprietary databases, Company/University
websites, SEC filings, investor presentations and
featured press releases from company/university
sites and industry-specific third party sources,
put together by Global Markets Directs team. Drug
profiles/records featured in the report undergoes
periodic updation following a stringent set of
processes that ensures that all the profiles are
updated with the latest set of information.
Additionally, processes including live news
deals tracking, browser based alert-box and
clinical trials registries tracking ensure that
the most recent developments are captured on a
real time basis. The report enhances decision
making capabilities and help to create effective
counter strategies to gain competitive advantage.
It strengthens RD pipelines by identifying new
targets and MOAs to produce first-in-class and
best-in-class products. Note Certain sections
in the report may be removed or altered based on
the availability and relevance of data for the
indicated disease.  
4
.
Report Overview
Scope The report provides a snapshot of the
global therapeutic landscape of Amyloidosis The
report reviews key pipeline products under drug
profile section which includes, product
description, MoA and RD brief, licensing and
collaboration details other developmental
activities The report reviews key players
involved in the therapeutics development for
Amyloidosis and enlists all their major and minor
projects The report summarizes all the dormant
and discontinued pipeline projects A review of
the Amyloidosis products under development by
companies and universities/research institutes
based on information derived from company and
industry-specific sources Pipeline products
coverage based on various stages of development
ranging from pre-registration till discovery and
undisclosed stages A detailed assessment of
monotherapy and combination therapy pipeline
projects Coverage of the Amyloidosis pipeline on
the basis of target, MoA, route of administration
and molecule type  
5
Report Overview
Reasons to buy  Provides strategically
significant competitor information, analysis, and
insights to formulate effective RD development
strategies Identify emerging players with
potentially strong product portfolio and create
effective counter-strategies to gain competitive
advantage Develop strategic initiatives by
understanding the focus areas of leading
companies Identify and understand important and
diverse types of therapeutics under development
for Amyloidosis Plan mergers and acquisitions
effectively by identifying key players of the
most promising pipeline Devise corrective
measures for pipeline projects by understanding
Amyloidosis pipeline depth and focus of
Indication therapeutics Develop and design
in-licensing and out-licensing strategies by
identifying prospective partners with the most
attractive projects to enhance and expand
business potential and Scope Modify the
therapeutic portfolio by identifying discontinued
projects and understanding the factors that drove
them from pipeline  
6
Table Of Contents
List of Tables 6List of Figures 7Introduction
8Global Markets Direct Report Coverage
8Amyloidosis Overview 9Therapeutics Development
10Pipeline Products for Amyloidosis - Overview
10Pipeline Products for Amyloidosis -
Comparative Analysis 11Amyloidosis -
Therapeutics under Development by Companies
12Amyloidosis - Therapeutics under Investigation
by Universities/Institutes 14Amyloidosis -
Pipeline Products Glance 15Late Stage Products
15Clinical Stage Products 16Early Stage
Products 17
7
Table Of Contents
Amyloidosis - Products under Development by
Companies 18Amyloidosis - Products under
Investigation by Universities/Institutes
20Amyloidosis - Companies Involved in
Therapeutics Development 21 Alnylam
Pharmaceuticals, Inc. 21Arcturus Therapeutics,
Inc 22Bellus Health Inc. 23Bsim2 24Celgene
Corporation 25GlaxoSmithKline Plc 26Isis
Pharmaceuticals, Inc. 27Millennium
Pharmaceuticals, Inc. 28Onyx Pharmaceuticals,
Inc. 29Pfizer Inc. 30ProteoTech, Inc. 31
8
Table Of Contents
Prothena Corporation Plc 32SOM Innovation
Biotech SL 33Amyloidosis - Therapeutics
Assessment 34Assessment by Monotherapy Products
34Assessment by Combination Products
35Assessment by Target 36Assessment by
Mechanism of Action 38Assessment by Route of
Administration 40Assessment by Molecule Type
42 Enquiry about this report _at_
http//www.researchbeam.com/amyloidosis-pipeline-r
eview-h2-2015-market/enquire-about-report

9
FOR MORE DETAILS
Visit us at
http//www.researchbeam.com/amyloidosis-pipeline-r
eview-h2-2015-market
Stay With Us
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE [phone] E-MAIL
sales_at_researchbeam.com